check_circleStudy Completed

Contraception

Bayer Identifier:

91460

ClinicalTrials.gov Identifier:

NCT01253187

EudraCT Number:

2005-003049-15

EU CT Number:

Not Available
Investigation of bioequivalence of ethinylestradiol (EE) and drospirenone (DRSP) in two different tablet formulations: YAZ and YAZ + levomefolate calcium (Metafolin) & L-5-MTHF in two different tablet formulations: levomefolate calcium (Metafolin) and YAZ + levomefolate calcium (Metafolin)

Trial purpose

The purpose of this study is examine and compare the uptake of YAZ (oral contraceptive containing drospirenone and ethinylestradiol) with or without levomefolate calcium (Metafolin, a registered vitamin supplement) in the body and to examine and compare the uptake of levomefolate calcium with or without YAZ in the body, in healthy volunteers not using hormonal contraception

Key Participants Requirements

Sex

Female

Age

18 - 38 Years
  • - Healthy female volunteer
    - Age: 18 – 38 years inclusive
    - Body mass index (BMI)1: ≥ 19 and < 28 kg/m²
    - Regular cyclic menstrual periods at screening OR when using combined oral contraceptives during the recruitment period reporting of natural cyclic menstrual periods prior to their use
    - Willingness to use non-hormonal methods of contraception during the complete trial OR previous tubal ligation
  • - incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, excretion and effect of the study drugs will not be normal
    - known or suspected sex-steroid influenced malignancies
    - endometrial hyperplasia; genital bleeding of unknown origin; uterus myomatosus
    - known or suspected tumors of the liver and pituitary
    - presence or history of severe hepatic disease as long as liver function values have not returned to normal
    - severe renal insufficiency or acute renal failure
    - thrombophlebitis, venous / arterial thromboembolic diseases; presence or history of prodromi of a thrombosis
    - other conditions that increase susceptibility to thromboembolic diseases
    - known neuropsychiatric diseases, especially known or suspected epilepsy, and/ or deficient status of folate or vitamin B12
    - use of any other medication within 2 cycles before first study drug administration which could affect the study aim
    - use of potassium sparing drugs; use of folic acid containing supplements or medicines or use of any medication within 2 cycles before first study drug administration known to interfere with folate metabolism
    - inadequate folate and/or Vitamin B12 status, clinically relevant deviations in red cell folate concentrations

Trial summary

Enrollment Goal
44
Trial Dates
October 2006 - September 2007
Phase
Phase 1
Could I Receive a placebo
No
Products
EE/DRSP/L-5-MTHF (BAY86-5131)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Dinox B.V.Groningen, 9713GZ, Netherlands

Primary Outcome

  • Mean maximum concentration (Cmax) of EE incl. bioequivalence (BE) evaluation
    date_rangeTime Frame:
    up to 96 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Mean Area Under the concentration-time Curve from administration to the last measurement [AUC(0-tlast)] of EE incl. bioequivalence (BE) evaluation
    date_rangeTime Frame:
    up to 96 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Mean maximum concentration (Cmax) of DRSP incl. bioequivalence (BE) evaluation
    date_rangeTime Frame:
    up to 168 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Mean Area Under the concentration-time Curve from administration to the last measurement [AUC(0-tlast)] of DRSP incl. bioequivalence (BE) evaluation
    date_rangeTime Frame:
    up to 168 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Mean maximum concentration (Cmax) of L-5-methyl-THF (baseline corrected) incl. bioequivalence (BE) evaluation
    date_rangeTime Frame:
    up to 12 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Mean Area Under the concentration-time Curve from administration to the last measurement [AUC(0-tlast)] of L-5-methyl-THF (baseline corrected) incl. bioequivalence (BE) evaluation
    date_rangeTime Frame:
    up to 12 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Mean maximum concentration (Cmax) of L-5-methyl-THF (baseline uncorrected) incl. bioequivalence (BE) evaluation
    date_rangeTime Frame:
    up to 12 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Mean Area Under the concentration-time Curve from administration to the last measurement [AUC(0-tlast)] of L-5-methyl-THF (baseline uncorrected) incl. bioequivalence (BE) evaluation
    date_rangeTime Frame:
    up to 12 hours after administration
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Time to reach maximum concentration (tmax) of EE
    date_rangeTime Frame:
    up to 96 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Mean Area Under the concentration-time Curve from administration up to 72h AUC(0-72h) of DRSP
    date_rangeTime Frame:
    up to 72 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Time to reach maximum concentration (tmax) of DRSP
    date_rangeTime Frame:
    up to 168 hours after administration
    enhanced_encryption
    Safety Issue:
    No
  • Time to reach maximum concentration (tmax) of L-5-methyl-THF
    date_rangeTime Frame:
    up to 12 hours after administration
    enhanced_encryption
    Safety Issue:
    No

Trial design

Open-label, randomized, three-fold crossover study to investigate the bioequivalence of two different tablet formulations containing 0.02 mg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) without [SH T00186D] and with [SH T04532B] 0.451 mg L-mefolinate (Metafolin), and to investigate the bioequivalence of two different tablet formulations containing 0.451 mg L-mefolinate (Metafolin) without [SH T04532C] and with 0.02 mg EE/ 3 mg DRSP [SH T04532B] in 42 healthy young women
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Open Label
Assignment
Crossover Assignment
Trial Arms
3

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer Healthcare products.